Compare KraneShares CSI China Internet ETF (KWEB) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? KraneShares CSI China Internet ETF trades at $24.11 (market cap $4.51B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: KraneShares CSI China Internet ETF and Travere Therapeutics Inc. Common Stock are close in size by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold KraneShares CSI China Internet ETF for 59 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| KWEB | TVTX | |
|---|---|---|
Market Cap | $4.51B | $4.88B |
Volume | 12,272,723 | 1,668,577 |
Sector | Sector/Thematic | Health |
52-Week High | $41.35 | $67.52 |
52-Week Low | $23.63 | $26.79 |
Typical Hold Time | 59 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $24.72, down 0.12% with neutral technical signals. The ETF faces mixed institutional activity amid ongoing U.S.-China trade dynamics. Recent news highlights China's economic challenges including industrial overcapacity and trade rebalancing pressures, while corporate profits showed a 26% Q2 surge according to Zacks Investment Research on September 8, 2026.
The outlook remains cautious due to geopolitical tensions and China's economic headwinds. Investment opportunity exists if U.S.-China relations improve, but risks include trade protectionism and domestic consumption weakness. Technical indicators suggest limited near-term momentum with key support at $25.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
